CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
96.51
+0.07 (+0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close96.44
Open96.34
Bid96.51 x 3000
Ask96.52 x 800
Day's Range96.20 - 97.15
52 Week Range58.59 - 97.15
Volume3,082,554
Avg. Volume6,849,487
Market Cap68.065B
Beta (3Y Monthly)1.82
PE Ratio (TTM)14.70
EPS (TTM)6.57
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est97.00
Trade prices are not sourced from all markets
  • Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
    PR Newswire2 days ago

    Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"

    Leoplus USA is developing Duet, a device and app which aims to support communications between people with MS and their care partners to help improve patients' disease management outcomes. "We know communication within families affected by multiple sclerosis can be challenging. Duet is an innovative way to create connections with those you love," said Tim Coetzee, Ph.D., Chief Advocacy, Services and Research Officer at the National Multiple Sclerosis Society, who served as chair of the judging panel.

  • Benzinga2 days ago

    The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...

  • Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
    Zacks2 days ago

    Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

    Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

  • Celgene (CELG) Stock Sinks As Market Gains: What You Should Know
    Zacks3 days ago

    Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Celgene (CELG) closed at $96.36, marking a -0.21% move from the previous day.

  • Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
    Zacks4 days ago

    Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop

    Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks4 days ago

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Boost Your Portfolio's Health With These 3 Big Drug Stocks
    Zacks4 days ago

    Boost Your Portfolio's Health With These 3 Big Drug Stocks

    The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

  • 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
    Motley Fool4 days ago

    5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

    New blockbusters could be on the way for five drugmakers.

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zacks5 days ago

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene
    Zacks5 days ago

    Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene

    Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene

  • Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
    InvestorPlace5 days ago

    Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

    Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.Source: Zynerba PharmaceuticalsThe stock was up 8% in pre-market trading and there's potential for this name to run even further once investors catch wind of it. We're seeing that play out now, with shares up 18% in Tuesday morning trading.With a market capitalization just under $250 million, it's not a well-known player like Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG). In the same light, it's not even a well-known cannabis stock, like Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB).InvestorPlace - Stock Market News, Stock Advice & Trading TipsZynerba was issued U.S. Patent No. 10,314,792, which is titled, "Treatment of Autism Spectrum Disorder with Cannabidiol" and runs through 2038. So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The PatentZynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. I say "potential" because there's still a lot of work and progress needed before this becomes a staple in the medicine cabinet, so to say. * 7 Dark Horse Stocks Winning the Race in 2019 The patented treatment "includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol." It was granted during the enrollment period of a Phase 2 BRIGHT study, which is intended to evaluate "the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder."Will it work? At this stage it's impossible to say, but there is promise. GW Pharmaceuticals (NASDAQ:GWPH) has successfully gained traction -- even here in the U.S. -- with its cannabidiol treatment for epileptic seizures. So if Zynerba can show similar successes with its treatment, it may open the door to other possible treatments in the future using its Zygel product. Trading ZYNE Stock Click to Enlarge The big boost in ZYNE stock comes as little surprise. After all, it's got all the right buzzwords working in its favor, even if the company has good intentions. Wall Street latches to these trends and investors aren't afraid to jump on board if they think there's opportunity. That's even as Phase-2 testing has yet to begin.ZYNE stock chart is one of only a few that could make a double-digit gain look fairly modest. Above you can see how it moved over downtrend resistance (blue line) on Monday. Now it's pushing through $13, as well as the 20-day moving average.Can this thing ignite through $14 and tag its 2019 high near $16.50? Yes, it can. There's no guarantee that it will, but these sort of momentum boosters can give a huge shot in the arm to small-cap stocks.Whether that justifies a move this powerful, ZYNE stock investors certainly have a reason to be excited. But there's a lot of room on the upside before Zynerba stock exhausts itself.On the downside, I want to see $11 to $11.50 hold as support.This marks the 50-day moving average (which is trending higher) as well as the 38.2% retracement. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday's gains. Bottom Line on ZYNE StockNorth of $13 and the 20-day would be best, but let's see how it trades throughout the day and the rest of this week.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.

  • CELG or VRTX: Which Is the Better Value Stock Right Now?
    Zacks5 days ago

    CELG or VRTX: Which Is the Better Value Stock Right Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
    Zacks5 days ago

    Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

    Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

  • Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate
    Zacks5 days ago

    Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Insider Monkey5 days ago

    Hudson Bay Capital Management’s Return, AUM, and Holdings (Part II)

    Read the beginning of this article here. At the end of the first quarter of 2019, Hudson Bay Capital Management held the most valuable stake in Liberty Expedia Holdings, Inc. (NASDAQ:LEXEA), an online travel company. The fund held 2.04 million Liberty Expedia’s shares with a value of $87.16 million, comprising only 1.14% of its diversified […]

  • 5 Solid Stocks Near 52-Week High Promise to Touch Peak Point
    Zacks6 days ago

    5 Solid Stocks Near 52-Week High Promise to Touch Peak Point

    Investors target stocks that are on a bullish run of late. Stocks witnessing price strength show a high chance of carrying the winning momentum forward.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELGView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CELG totaled $14.28 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CNW Group6 days ago

    GT Biopharma Company Update

    GT Biopharma Company Update

  • Celgene (CELG) Gains But Lags Market: What You Should Know
    Zacks9 days ago

    Celgene (CELG) Gains But Lags Market: What You Should Know

    Celgene (CELG) closed the most recent trading day at $96.04, moving +0.89% from the previous trading session.

  • Celgene's Filing for Ozanimod Accepted for Review in US/EU
    Zacks9 days ago

    Celgene's Filing for Ozanimod Accepted for Review in US/EU

    The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

  • 2 Dividend Stocks to Buy That Are Better Than 3M Stock
    InvestorPlace9 days ago

    2 Dividend Stocks to Buy That Are Better Than 3M Stock

    InvestorPlace columnist James Brumley recently discussed the pros and cons of owning 3M (NYSE:MMM) stock. He concluded that, despite 3M's shrinking profits, MMM stock might be a falling knife worth catching. Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsBrumley believes the things that ail MMM aren't insurmountable and that MMM stock price has been beaten down due to noise and fear. It's hard to argue with his rationale. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% MMM stock has fallen 25% in the past six weeks since announcing weaker-than-expected Q1 2019 earnings, lower guidance for the remainder of 2019, and the cutting of 2,000 jobs. But since the Q1 earnings were released, there's been little new information to justify the ongoing bloodletting iof 3M stock. MMM now yields 3.61%, a very healthy return for anyone looking for dividend stocks to buy. While I believe 3M stock is an excellent long-term investment, I also think that investors looking for high dividends can find better stocks to buy.Here are two possible ideas. Synovus Financial (NYSE:SNV)Currently yielding 3.66%, the Georgia regional bank has fallen 2.65% in 2019. Recently, Synovus named Jamie Gregory, a Regions Bank (NYSE:RF) executive vice president and head of corporate financial strategy, as its new CFO, replacing Kevin Blair, who was promoted to COO in December. Gregory has a strong background in corporate finance, which is critical in a highly competitive industry. Not only that, but he brings an understanding of community banking to Synovus. In the first quarter, Synovus's adjusted earnings per share grew by 7.6% sequentially and 15.5% on a year- over-year basis. Its adjusted efficiency ratio, which shows how efficiently the bank operated in the quarter, was 50.24%, 7.18 percentage points lower than a year ago. Lower is always good when it comes to this metric.Thanks to SNV's acquisition of FCB Financial Holdings, the owner of the Florida Community Bank, in January, Synovus added more than $9 billion in loans to its portfolio, which stood just shy of $36 billion at the end of March. As the south continues to grow, so, too, will Synovus. Bristol-Myers Squibb (NYSE:BMY)Currently yielding 3.51%, the New York-based pharmaceutical company on Apr. 25 released better-than-expected Q1 earnings, which temporarily put some air under BMY stock. But it has since fallen back towards the mid-$40s. Bristol-Myers' first-quarter earnings per share came in at $1.10, 17% higher than a year earlier and one penny better than analysts' average estimate. On the top line, its revenue was $5.92 billion, 14% higher than a year earlier, and $170 million higher than analysts' consensus outlook. On June 5, Bristol-Myers announced the leadership team that will run the company once it completes its $74-billion acquisition of Celgene (NASDAQ:CELG) later this year. In a key move, its research and development will be divided into an early- phase development team and a late-phase development team, with a Celgene executive handling the early-phase development group and a former Novartis (NYSE:NVS) executive running the late-phase development efforts. Celgene CFO David Elkins will replace Bristol Myer's CFO Charles Bancroft, who is retiring. Current BMY CEO Giovanni Caforio will run the combined business.Look for several of Celgene's drugs that are now in the pipeline to get FDA approval later this year and into 2020. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage Compare Brokers The post 2 Dividend Stocks to Buy That Are Better Than 3M Stock appeared first on InvestorPlace.

  • Novartis Appoints New Pharma Unit Head, Gives Other Updates
    Zacks9 days ago

    Novartis Appoints New Pharma Unit Head, Gives Other Updates

    Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

  • Reuters9 days ago

    UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO

    * Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 (Reuters) - Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest move by a Novartis executive to a competitor.

  • Reuters9 days ago

    CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO

    Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday. Hudson will take over on Sept. 1, Sanofi said, confirming a Reuters report published on Thursday and marking the latest transfer of a Novartis executive to a competitor. UK-born Hudson, 51, has been CEO of the Novartis Pharmaceuticals, one of the Swiss company's three main divisions, since 2016.

  • Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally
    Yahoo Finance Video9 days ago

    Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally

    Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.